Business Wire

Breaking News: B2Prime Acquires a Security Dealer License in Seychelles, Expanding Global Operations

30.4.2024 15:30:00 EEST | Business Wire | Press release

Share

B2B Prime Services SC Ltd, a multi-asset Prime of Prime liquidity provider, has achieved another significant regulatory milestone by obtaining a security dealer license in Seychelles. This marks the third license for B2Prime, following those in Cyprus and Mauritius. These jurisdictions serve as key hubs with a high concentration of brokers, and B2Prime is dedicated to serving regulated market participants not only in these locations but also throughout Europe. This latest license underscores B2Prime's commitment to providing trusted and compliant services to its global client base.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430008885/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

B2Prime, a globally renowned multi-asset Prime of Prime liquidity provider, has obtained a security dealer license in Seychelles, expanding its global operations and opening doors to its top-tier liquidity services for local brokers, hedge funds, money managers, institutional clients, and liquidity providers. (Photo: Business Wire)

Seychelles, recognised as a crucial hub for brokers, provides B2Prime with a strategic platform to distribute liquidity locally across all regulated companies.

The newly acquired security dealer license enables the B2Prime group to engage in crucial financial activities, such as negotiating and entering agreements for acquiring, disposing of, subscribing for, or underwriting securities. Additionally, it allows to manage securities transactions, handle sales, and manage portfolios of securities on behalf of the clients.

This significant development will greatly enhance the ability to operate efficiently within global markets, backed by a robust legal framework to offer these services under the strict regulatory oversight of the Seychelles Financial Services Authority (SFSA).

Importance of Seychelles License for B2Prime Clients

Seychelles is becoming an attractive location for brokerages, thanks to its strategic placement between Africa, Asia, and the Middle East and its supportive financial climate. With 182 brokers already registered in Seychelles, there is a clear need for a local liquidity partner that can streamline operations and offer advanced financial and technology solutions.

In response to this demand, B2Prime has strategically expanded its presence by acquiring a security dealer license from the Seychelles Financial Services Authority (SFSA), the regulatory body responsible for the licensing and supervision of financial service providers, including security dealers.

This development eliminates the need for local companies to seek out or connect with liquidity providers in distant financial hubs. Instead, they can directly access B2Prime’s extensive Prime of Prime level liquidity.

B2Prime offers over 225 instruments across six asset classes in CFDs, including FOREX, Cryptos, Spot Indices, Precious Metals, Commodities, and NDFs, all through a single margin account. B2Prime clients benefit from deep liquidity pools sourced from Tier-1 providers, which ensure tight spreads and ultra-fast execution. Connectivity options, including OneZero, PXM, Centroid, T4B, FIX API, and cTrader, further facilitate seamless integration and efficiency.

“Establishing our operations in Seychelles opens doors to our Prime of Prime liquidity and enhanced service levels for local brokers, hedge funds, money managers, institutional clients, and liquidity providers. This step forward aligns perfectly with our goal of providing top-tier financial services worldwide and enables us to offer even greater reliability and seize new opportunities in global markets.”

– Eugenia Mykulyak, Founder & Executive Director of B2Prime

Robust Financial Performance and Future Outlook

Following the strategic initiatives, B2Prime has recently disclosed the financial results for its parent company, B2B Prime Services EU, which highlights robust financial growth in the first quarter of 2024. Total assets in Cyprus surged to €28,969,690.98, a 40.32% increase from the previous year. Client assets held for trading also increased by 47.6% to €26,840,460.11.

In the same period, the shareholders' equity rose by 8%, with year-on-year comparisons showing a 68% growth in total assets and a 64% increase in client assets held for trading. Notably, shareholders' equity experienced an impressive 289% surge. Regulatory Capital Adequacy dramatically improved, too, with B2Prime's own funds soaring nearly 600% from €503,000 to €2,728,000, far exceeding regulatory minimums with CET1 and Tier 1 ratios significantly above the required standards.

These figures highlight a strong balance sheet and show B2Prime’s ongoing devotion to growth and reliability. Soon, the company will also disclose the fiscal report for B2Prime Mauritius, which will further validate its position as a credible and reliable service provider to clients worldwide.

Final Remarks

B2Prime has been actively expanding its global footprint since its establishment in Cyprus in 2020 and Mauritius in 2023. The ongoing strategy aims to position B2Prime as a trusted partner in key financial jurisdictions worldwide. The recent acquisition of a security dealer license in Seychelles is a continuation of these efforts to offer Prime of Prime financial services and exclusive tools to local businesses in Seychelles, enhancing their capabilities and potential to succeed in the global marketplace.

The company is thrilled to start operating as a trusted liquidity provider in Seychelles and partner with local businesses!

Reach out today for market-leading liquidity solutions!

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

+230 46 555 26
info@b2prime.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 14:30:00 EEST | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin

Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release

Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user

Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release

Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin

Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye